Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ABOBOTULINUM TOXIN A

All injection strengths: Limited Use (codes 130, 412, 413)

Dysport Therapeutic · DIN 02456117 · 500U/Vial · Pd injection-vial

Limited Use — Reason for Use code 130, 412, 413 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 130, 412, 413 required
Write on scriptLU code 130, 412, 413 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 130, 412, 413
Coverage limit: Dysport Therapeutic should be administered personally by a neurologist, pediatrician, or a physician with equivalent post-graduate training and experience with neuromuscular disorders. Reason for Use code 130 To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults. Coverage limit: LU Authorization Period: 1 year Reason for Use code 412 For the management of focal spasticity, due to stroke or spinal cord injury in adults. Coverage limit: LU Authorization Period: 1 year Reason for Use code 413 For the treatment of focal spasticity secondary to cerebral palsy in patients two years of age or older. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Dysport Therapeutic · DIN 02456117 Manufacturer: Ipsen Limited; listing date 2018-09-27 Health Canada: Marketed since 2022-04-06 · brand DYSPORT THERAPEUTIC · ATC M03AX01 BOTULINUM TOXIN · form Powder for solution · route Intramuscular · ingredients ABOBOTULINUMTOXINA 500 UNIT/VIAL · company Ipsen biopharmaceuticals canada inc · schedule Schedule d, Prescription
Check this DIN again · Health Canada product record

Dysport Therapeutic: Formulary list price $642.6000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $642.6000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94296 · Verify on the e-Formulary ↗ (DIN 02456117)

Source record
DIN 02456117: Dysport Therapeutic Raw flags: sec12=Y, sec3=Y Item: 929200002; group id 1047; item number 2402; lccId 00308; manufacturer id IPS Source form: Pd Inj-Vial Pk; strength: 500U/Vial Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $642.6000; ministry $642.6000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456117 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94296
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456117
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (92:92 Other Miscellaneous Therapeutic Agents) and how they are covered

Matched class: 92:92 Other Miscellaneous Therapeutic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 92:92 Other Miscellaneous Therapeutic Agents

FAMPRIDINE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:92
Full class listing Related classes: 92:20 Biologic Response Modifiers, 92:36 Disease-Modifying Antirheumatic Agents, 92:44 Immunosuppressive Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS DYSPORT THERAPEUTIC (abobotulinumtoxinA) is indicated: Cervical Dystonia • To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults Focal Spasticity • For the symptomatic treatment of focal spasticity affecting the upper and lower limbs in patients 2 years of age and older 1.1 Pediatrics Pediatrics (< 18 years of age): Safety and effectiveness in pediatric patients below 2 years of age have not been evaluated. Dysport Therapeutic is not recommended for use in pediatric patients less than 18 years of age in the treatment of cervical dystonia. 1.2 Geriatrics Geriatrics (> 65 years of age): The clinical data for subjects > 65 years of age are limited. https://pdf.hres.ca/dpd_pm/00075715.PDF PM date: JUN 12, 2012 Source product: DYSPORT THERAPEUTIC; DIN 02456117; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.